|
Research And Markets - View These Extensive Reviews Focused On Pharmacology, Pharmacokinetics, Toxicology, And Clinical Trials Of New Or Potential Cardiovascular Drugs
Research and Markets (researchandmarkets.com/reports/c9291) has announced the addition of Cardiovascular Drug Reviews to their offering.
(PRWEB) November 17, 2004 -- Cardiovascular Drug Reviews focuses on extensive reviews on the pharmacology, pharmacokinetics, toxicology, and clinical trials of new or potential cardiovascular drugs. These peer-reviewed articles are written by industrial or academic scientists who participated in the development of a particular drug. The Editorial Board is composed of eminent and highly reputable scientists.
Research and Markets (http://www.researchandmarkets.com/reports/c9291) has announced the addition of Cardiovascular Drug Reviews to their offering.
Subscribe to Cardiovascular Drug Reviews to receive:
- Timely summaries of clinical studies for newly FDA approved or potential drugs.
- Insight into the biological activity of novel chemical entities.
- Valuable information on pharmacokinetics and associated ADME properties.
You Should Subscribe to Cardiovascular Drug Reviews to:
- Identify toxicity and suboptimal characteristics as competitive opportunities.
- Recognize actionable information across all functional areas, including discovery, development, and clinical use.
- Be up-to-date on new drug developments most significantly affecting the cardiovascular drug market.
- Receive quality information on new drugs that is peer-reviewed by an eminent, international Editorial Board.
The following individuals will benefit from a subscription to Cardiovascular Drug Reviews:
- Cardiologists
- Clinical Pharmacologists
- Drug Development Scientists
- Internists
- Medicinal Chemists
- Pharmaceutical Industry Executives
- Pharmacologists
- Toxicologists
For more information visit http://www.researchandmarkets.com/reports/c9291
Laura Wood
Senior Manager
Research and Markets
press@researchandmarkets.com
Fax: +353 1 4100 980
###
|
